Gilead Signs an Exclusive Worldwide License Agreement with Durect for its HIV and Hepatitis B Products
Shots:
- Durect to receive $25M up front- ~$145M milestones including ~$75M for development & regulatory and ~$70M on sales plus royalties on sales of products. Gilead to get exclusive WW rights to develop and commercialize a long-acting injectable HIV product based on Durect's SABER technology
- Gilead also has an exclusive right to access Durect’s SABER platform for HIV and Hepatitis B Virus with an option to license SABER-based products for HIV and HBV. If the option is exercised- Gilead will pay $150M/product in up front- development- regulatory and sales-based milestones plus royalties on sales
- Durect's SABER Technology (Sucrose acetate isobutyrate extended release) is used to provide sustained release of long-acting injectable products. Posimir (bupivacaine extended release solution) is locally acting- non-opioid analgesic based on SABER Technology
Click here to read full press release/ article | Ref: Durect | Image: Bastiaan Aalbersberg
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com